Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Ruth Milz, Carmela Benson, Karl Knight, Jose Antunes, Dean Najarian, Paola-Maria Lopez Rengel, Steven Wang, Ute Richarz, Srihari Gopal & John M Kane. (2023) The Effect of Longer Dosing Intervals for Long-Acting Injectable Antipsychotics on Outcomes in Schizophrenia. Neuropsychiatric Disease and Treatment 19, pages 531-545.
Read now
Read now
Giovanna Cirnigliaro, Vera Battini, Rita Cafaro, Giulia Mosini, Simone Vanzetto, Tiziano Prodi, Monica Macellaro, Rodolfo Leuzzi, Dario Conti, Carla Carnovale & Bernardo Dell’Osso. (2023) Barriers to the use of three-month Paliperidone Palmitate formulation: a study from an Italian real-world setting. Expert Review of Neurotherapeutics 23:11, pages 1031-1039.
Read now
Read now
Gang Li, Alexander Keenan, Mehmet Daskiran, Maju Mathews, Isaac Nuamah, Camille Orman, Kruti Joshi, Arun Singh, Annabelle Godet, Katalin Pungor & Srihari Gopal. (2021) Relapse and Treatment Adherence in Patients with Schizophrenia Switching from Paliperidone Palmitate Once-Monthly to Three-Monthly Formulation: A Retrospective Health Claims Database Analysis. Patient Preference and Adherence 15, pages 2239-2248.
Read now
Read now
Antoine C El Khoury, Charmi Patel, Panagiotis Mavros, Ahong Huang, Li Wang & Richa Bashyal. (2021) Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate Among Veterans with Schizophrenia. Neuropsychiatric Disease and Treatment 17, pages 3159-3170.
Read now
Read now
Amy O’Donnell, Sanjai Rao, Ibrahim Turkoz, Srihari Gopal & Edward Kim. (2021) Defining “Adequately Treated”: A Post Hoc Analysis Examining Characteristics of Patients with Schizophrenia Successfully Transitioned from Once-Monthly Paliperidone Palmitate to Once-Every-3-Months Paliperidone Palmitate. Neuropsychiatric Disease and Treatment 17, pages 1-9.
Read now
Read now
Alicia Lopez & Jose Rey. (2019) Role of paliperidone palmitate 3-monthly in the management of schizophrenia: insights from clinical practice. Neuropsychiatric Disease and Treatment 15, pages 449-456.
Read now
Read now
Bruno Emond, Antoine C. El Khoury, Charmi Patel, Dominic Pilon, Laura Morrison, Maryia Zhdanava, Patrick Lefebvre, Neeta Tandon & Kruti Joshi. (2019) Real-world outcomes post-transition to once-every-3-months paliperidone palmitate in patients with schizophrenia within US commercial plans. Current Medical Research and Opinion 35:3, pages 407-416.
Read now
Read now
Miquel Bioque & Miquel Bernardo. (2018) The current data on the 3-month paliperidone palmitate formulation for the treatment of schizophrenia. Expert Opinion on Pharmacotherapy 19:14, pages 1623-1629.
Read now
Read now
Claudio Brasso, Silvio Bellino, Paola Bozzatello, Cristiana Montemagni & Paola Rocca. (2017) Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia. Neuropsychiatric Disease and Treatment 13, pages 2767-2779.
Read now
Read now
Articles from other publishers (13)
Ibrahim Turkoz, Mehmet Daskiran, Uzma Siddiqui, R Karl Knight, Karen L Johnston & Christoph U Correll. (2024) Relapse Rates With Paliperidone Palmitate in Adult Patients With Schizophrenia: Results for the 6-Month Formulation From an Open-label Extension Study Compared to Real-World Data for the 1-Month and 3-Month Formulations. International Journal of Neuropsychopharmacology 27:2.
Crossref
Crossref
Chien-Heng Lin, Huang-Li Lin, Chih-Lin Chiang, Yi-Wen Chen, Yan-Fang Liu, Yen-Kuang Yang & Chao-Hsiun Tang. (2023) Treatment Retention Rates of 3-monthly Paliperidone Palmitate and Risk Factors Associated with Discontinuation: A Population-based Cohort Study. Clinical Psychopharmacology and Neuroscience 21:3, pages 544-558.
Crossref
Crossref
Sophie Hirsch, Johanna Baumgardt, Andreas Bechdolf, Felix Bühling-Schindowski, Celline Cole, Erich Flammer, Lieselotte Mahler, Rainer Muche, Dorothea Sauter, Angelika Vandamme & Tilman Steinert. (2023) Implementation of guidelines on prevention of coercion and violence: baseline data of the randomized controlled PreVCo study. Frontiers in Psychiatry 14.
Crossref
Crossref
Joshua Lambert, Harpal Sandhu, Emily Kean, Teenu Xavier, Aviv Brokman, Zachary Steckler, Lee Park & Arnold Stromberg. (2022) A strategy to identify event specific hospitalizations in large health claims databases. BMC Health Services Research 22:1.
Crossref
Crossref
Xiuru Su, Long Zhao, Yujie Shang, Yingnan Chen, Xiaowen Liu, Xuan Wang, Meihong Xiu, Huijing Yu & Lijun Liu. (2022) Repetitive transcranial magnetic stimulation for psychiatric symptoms in long-term hospitalized veterans with schizophrenia: A randomized double-blind controlled trial. Frontiers in Psychiatry 13.
Crossref
Crossref
C.H. Lin, H.L. Lin, C.L. Chiang, Y.W. Chen, S.P. Wang, Y.F. Liu, Y.K. Yang & C.H. Tang. (2021) P.0161 Successful transition from 1-monthly to 3-monthly paliperidone palmitate and its associative factors in patients with schizophrenia: a population-based cohort study. European Neuropsychopharmacology 53, pages S117-S118.
Crossref
Crossref
Natalia N. Petrova & Valeria S. Serazetdinova. (2020) Long-Acting Injectable Drugs in the Maintenance Therapy of Patients with Schizophrenia. Consortium Psychiatricum 1:2, pages 53-62.
Crossref
Crossref
Karel Kostev, Galina Osina & Marcel Konrad. (2019) Treatment Patterns of Patients with Schizophrenia Based on the Data from 44,836 Outpatients in Russia. Heart and Mind 3:4, pages 161-164.
Crossref
Crossref
Charmi Patel, Antoine El Khoury, Ahong Huang, Li Wang, Onur Baser & Kruti Joshi. (2019) Health Outcomes Among Patients Diagnosed with Schizophrenia in the US Veterans Health Administration Population Who Transitioned from Once-Monthly to Once-Every-3-Month Paliperidone Palmitate: An Observational Retrospective Analysis. Advances in Therapy 36:10, pages 2941-2953.
Crossref
Crossref
Bruno Emond, Kruti Joshi, Antoine C. El Khoury, Marie-Hélène Lafeuille, Dominic Pilon, Neeta Tandon, Hela Romdhani & Patrick Lefebvre. (2018) Adherence, Healthcare Resource Utilization, and Costs in Medicaid Beneficiaries with Schizophrenia Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate. PharmacoEconomics - Open 3:2, pages 177-188.
Crossref
Crossref
Maral DerSarkissian, Patrick Lefebvre, Kruti Joshi, Brianne Brown, Marie-Hélène Lafeuille, Rachel H. Bhak, Michael Hellstern, Priyanka Bobbili, Brian Shiner, Antoine C. El Khoury & Yinong Young-Xu. (2018) Health Care Resource Utilization and Costs Associated with Transitioning to 3-month Paliperidone Palmitate Among US Veterans. Clinical Therapeutics 40:9, pages 1496-1508.
Crossref
Crossref
Anirban BasuCarmela BensonLarry Alphs. (2018) Projecting the Potential Effect of Using Paliperidone Palmitate Once-Monthly and Once-Every-3-Months Long-Acting Injections Among Medicaid Beneficiaries with Schizophrenia. Journal of Managed Care & Specialty Pharmacy 24:8, pages 759-768.
Crossref
Crossref
Michael W. Jann & Scott R. Penzak. (2018) Long-Acting Injectable Second-Generation Antipsychotics: An Update and Comparison Between Agents. CNS Drugs 32:3, pages 241-257.
Crossref
Crossref